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SUMMARY  A  40-year-old male patient with primary aneto- 
derma is presented in whom antiphospholipid antibodies 
were detected while not fulfilling diagnostic criteria for 
antiphospholipid syndrome. The possible pathogenic role of 
antiphospholipid antibodies in the disease development is 
postulated.
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INTRODUCTION
 The term anetoderma has been derived from 
the Greek words anetos meaning slack and derma 
meaning skin. The term was introduced in 1891 
by Jadassohn to describe a rare elastolytic dis-
order characterized by limited areas of slack skin 
associated with dermis reduction, determined by 
palpation, while the loss of elastic tissue is demon-
strated by histopathology (1). There are two forms 
of anetoderma, idiopathic and secondary type. Id-
iopathic or primary anetoderma occurs in clinically 
intact skin and is not preceded by any specific der-
matosis (2,3). Secondary anetoderma develops 
at sites previously affected by well defined dis-
eases of inflammatory (4-7) or tumorous genesis 
(8-11). Now the clinical classification of primary 
anetoderma into inflammatory (Jadassohn-Pelliz-
ari) and noninflammatory (Schweninger-Buzzi) is 
exclusively of historical relevance because the 
two types of the disease may coexist in the same 
patient. Histologically, the two types of the disease 
are almost identical. Furthermore, inflammatory 
infiltration is present in both types of the disease, 
and clinical presence or absence of inflamma-
tion at the disease onset has no prognostic value 
(1,12). Rare familial cases of the disease (13,14) 
and its occurrence in premature infants (15,16) 
have also been described.
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 The cause of primary anetoderma has not yet 
been clearly identified, however, the role of im-
mune mechanisms in the occurrence of elastoly-
sis and primary anetoderma has been increasingly 
implicated.
 The aim of this report is to point to the possible 
etiopathogenetic role of antiphospholipid antibod-
ies in the development of anetoderma.
CASE REPORT
 Our patient was a 40-year-old man, a Romany, 
with 9-year history of asymptomatic atrophic skin 
lesions gradually increasing in number. The diag-
nosis of anetoderma had been made by biopsy 
4 years before, however, the patient received no 
therapy. There was no family history of similar skin 
lesions. The patient had no serious diseases in his 
personal medical history, except for chickenpox 
and infectious jaundice in childhood. There were 
no data on thrombotic events. During hospitaliza-
tion, the patient complained of vertigo and hyperhi-
drosis. Physical examination was unremarkable.
 Nine oval or round, slack, outpouching, elevat-
ed foci with positive herniation phenomenon, fine-
ly wrinkled surface, up to 6 cm in diameter were 
observed on the skin of the trunk and upper arms 
(Fig. 1, Figs. 2 a and b). Eight foci were flesh-col-
ored, while only one focus was erythematous and 
mildly elevated (Fig. 3). Other skin and mucosal 
areas showed no alterations.
x-ray, heart and lung x-ray; abdominal ultrasonog-
raphy; Doppler ultrasonography of lower extrem-
ity circulation; ophthalmologic and neurologic ex-
aminations; and direct immunofluorecence in the 
affected skin were negative or within the normal 
limits.
 Erythrocyte sedimentation rate (ESR), red, 
white and differential blood counts (RBC, WBC and 
DBC); routine biochemistry tests; electrophoresis 
and immunoelectrophoresis; ANF, ADNA; anti Ro, 
anti La; total complement, complement C3 and C4 
fractions; PTT, APTT; fibrinogen; hepatitis mark-
ers; anti HIV1 and anti HIV2; VDRL, TPHA, PPD 
test, ACE; T3, T4, TSH; ECG; EEG; cervical spine 
Figure 1. Atrophic foci on the skin of the trunk and 
upper arms.
Figures 2 a and b. Flesh colored, outpouching, 
atrophic foci (a), with finely wrinkled surface (b).
Figure 3. Erythematous and slightly elevated 
focus on the left side of the chest that appeared 
recently.
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Figure 2b.
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 The following findings were borderline positive 
or pathologic: titer of IgG antibodies to Borrelia 
burgdorferi (indirect immunofluorescence) and 
level of circulating immunocomplexes. Thrombo-
cytopenia was present (Plt: 103, 113, n 158-424). 
Flow cytometry indicated mild to moderate serum 
reactivity with healthy donor platelets, indicating 
unbound platelet reactive antibodies (that may 
have corresponded to antiphospholipid antibod-
ies); no bound antiplatelet IgG antibodies were 
detected. Positive anticardiolipin antibodies (aCL) 
and lupus anticoagulant (LAC) were found on two 
occasions 7 weeks apart; aCL antibodies were 
determined by ELISA: aCL-IgM 41, 45 MPL U/ml 
(high positive value >30) and aCL-IgG 23, 30 GPL 
U/ml (moderate positive value 20-40). LAC was 
determined by use of coagulation tests, diluted 
Russel’s viper venom time (dRVVT), activated 
partial thromboplastin time (aPTT) and kaolin clot-
ting time (KCT).
a skin specimen obtained by initial biopsy 4 years 
before, inflammatory infiltrates located in vascu-
lar walls and perivascularly, along with endothelial 
lesion and vein discontinuation along cutaneous-
subcutaneous border were observed (Figs. 6 a 
and b). There were no intraluminal microthrombi.
 Based on the clinical picture, laboratory find-
ings and skin histopathology, the diagnosis of 
primary anetoderma with coexisting thrombocyto-
penia and antiphospholipid antibodies was made. 
The patient had no other classification criteria for 
antiphospholipid syndrome.
 The patient was administered azithromycin for 
5 days as follows: day 1, 2x1 500 mg capsule, 
then 1x1 500 mg capsule/day for the next 4 days. 
Antiaggregation therapy with acetylsalicylic acid 
(Andol) at a dose of 100 mg/day was introduced 
as a thrombotic event prophylaxis.
 On control examination two new, round foci, 2 
cm in diameter, were observed on the trunk. The 
patient was recommended continuous monitoring 
and control internal-medicine examinations for 
positive antiphospholipid antibodies and potential 
development of thrombosis.
Figure 4. Scanty, perivascular lymphocytic infiltrate 
in the dermis (H&E, original magnification x25).
 Histopathologic examination of the atrophic fo-
cus (upon excision biopsy performed by a plastic 
surgeon) revealed scanty perivascular lympho-
cytic infiltrate (Fig. 4) and almost complete intra-
dermal loss or fragmentation of elastic fiber (Fig. 
5). On serial section of a paraffin block containing 
Figure 5. Almost complete intradermal loss, or 
fragmentation of elastic fiber (Orcein, original 
magnification x25).
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DISCUSSION
 To date, several hundred patients with aneto-
derma have been described in the world (1). The 
pathogenesis of the disease remains unknown. 
Almost identical pathogenetic mechanisms have 
been postulated for primary and secondary aneto-
derma, both forms being predominated by the loss 
of dermal elastin that may be due to its increased 
destruction or decreased synthesis (1). A congeni-
tal elastin defect has been postulated in familial 
cases of the disorder (13). Many theories, espe-
cially those on secondary anetoderma following 
inflammation, try to explain the mechanism of an-
etoderma development by an increased destruc-
tion of elastic fiber, i.e. by an enhanced release 
of elastases and cytokines such as IL-6 from in-
flammatory cells; increased progelatinose A and B 
synthesis; or elastic fiber phagocytosis by macro-
phages (4-7). It should be noted that an impaired 
balance between metalloproteinases and their tis-
sue inhibitors has been demonstrated in affected 
skin samples (17). Skin hypoxia may act as a trig-
ger for this balance impairment (18). Ischemic pro-
cess has also been implicated as a possible cause 
of anetoderma in premature infants at the sites of 
skin contact with leads for ECG or EEG (15).
 As clinical or laboratory signs of autoimmunity 
are quite commonly observed in patients with an-
etoderma, the association between anetoderma 
and immune mechanisms has been investigated 
with increased frequency, especially since 1990. 
So, patients with anetoderma have been observed 
to frequently show positive direct immunofluores-
cence in the affected skin in the form of linear or 
granular immunoglobulin and/or complement de-
posits along the dermoepidermal junction, and oc-
casionally also perivascularly (19).
 Anetoderma has also been described in asso-
ciation with various autoimmune disorders, e.g., 
discoid lupus erythematosus, systemic lupus ery-
thematosus, alopecia areata, vitiligo, Hashimoto’s 
thyroiditis, Graves’ disease, Addison’s disease, 
and systemic scleroderma (19). Yet, systemic lu-
pus erythematosus, discoid lupus erythematosus 
and lupus profundus are autoimmune disorders 
that have been most commonly associated with 
anetoderma.
 Anetoderma association with various antibod-
ies has also been reported (20). The antibodies 
most commonly associated with anetoderma are 
positive ANF, false positive classic serologic re-
action to syphilis or Borrelia burgdorferi, and an-
tiphospholipid antibodies. Some antibodies are 
rarely detected, such as antibodies to proliferating 
cell nuclear antigen (anti-PCNA) (21), whereas 
others such as anticardiolipin IgA antibodies have 
not yet been routinely introduced in practice. The 
association of positive antiphospholipid antibod-
ies and anetoderma has been investigated. To 
date more than 20 primary anetoderma patients 
have been described in whom antiphospholipid 
antibodies (LAC and/or aCL) and/or antibody to 
β2-glycoprotein I (aβ2-GpI) were demonstrated 
as an isolated laboratory finding, or as part of the 
antiphospholipid syndrome, or in relation to some 
other clinical and/or laboratory signs of autoimmu-
nity (21-24). Anetoderma was also recorded dur-
ing the course of HIV infection (25). Lindstrom et 
al. found a correlation between elevated aCL titer 
and occurrence of anetoderma, usually second-
ary, in HIV positive patients (26).
 For the matter of convenience, here is an over-
view of the antiphospholipid syndrome features. 
Antiphospholipid syndrome is an acquired multi-
system coagulation disorder that may occur as a 
primary or secondary type. Primary antiphospho-
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Figures 6a and b. Inflammatory lymphocyte infiltra- 
tes in vascular walls and perivascularly (H&E, 
original magnification x25) (a), and endothelial 
lesion of a vein with endothelial discontinuation 
(H&E, original magnification x50)
Figure 6a.
Figure 6b.
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lipid syndrome is more common and is diagnosed 
in patients with antiphospholipid antibodies and 
thrombosis, without associated comorbidity. Sec-
ondary antiphospholipid syndrome is associated 
with a broad array of diseases including systemic 
lupus erythematosus and other autoimmune dis-
eases. The diagnosis of antiphospholipid syn-
drome is based on the presence of any of the fol-
lowing major criteria: arterial thrombosis, venous 
thrombosis, habitual abortion, and thrombocyto-
penia (as an accessory sign), along with the pres-
ence of LAC and aCL. Cutaneous manifestations 
include livedo reticularis, necrotizing vasculitis, 
livedoid vasculitis, thrombophlebitis, erythema-
tous maculae and purpura (27), and very rarely 
described anetoderma (28).
 In these patients, laboratory workup should in-
clude all biochemistry tests available for detection 
of antiphospholipid antibodies (LAC, all aCL iso-
types, aβ2-GpI). Anticardiolipin IgA antibodies, anti 
β2-GpI antibodies, and antibodies to phosphotidyl 
serine, prothrombin, anexin V, protein C and pro-
tein S have not yet been included among recog-
nized criteria for verification of the disease (27). In 
some patient subgroups only positive lupus anti-
coagulant with negative anticardiolipin antibodies 
or negative anti β2-GpI antibodies can be demon-
strated, whereas others may show only positive 
anticardiolipin antibodies with negative lupus an-
ticoagulant. Also, there are patients with positive 
LAC and aCL findings. Therefore, when antiphos-
pholipid syndrome is considered on differential di-
agnosis, it does not appear acceptable to deter-
mine only one type of antibodies (27). The exact 
mechanism of thrombophilic state induction by 
antiphospholipid antibodies remains to be clarified 
(27,29). The antibodies may react with platelets, 
whereafter they release their cellular constituents 
to form a clot. Also, the antibodies may bind to the 
endothelial cell surface, thus rendering the other-
wise nonreactive endothelial cell surface reactive 
to circulating blood constituents to form a clot. In 
normal conditions, hexagonal phospholipids of 
endothelial cells are bound via β2-GpI prothrom-
bin, a phospholipid binding protein, thus render-
ing endothelial cells nonreactive. However, in an-
tiphospholipid syndrome, the normal phospholipid 
binding protein (β2-GpI prothrombin) cannot bind 
to endothelial cell because the site has been oc-
cupied by the phospholipid antibody or its plasma 
level has been reduced (27).
 As for the role of antiphospholipid syndrome in 
the pathophysiology of anetoderma, some authors 
have postulated that dermal vessel microthrom-
boses lead to focal ischemia, followed by dermal 
elastic fiber destruction (23). This hypothesis has 
been supported by the finding of microthrombi de-
scribed in skin biopsy specimens of patients with 
primary anetoderma associated with antiphospho-
lipid antibodies (30).
 As differentiated from other cutaneous mani-
festations of antiphospholipid syndrome, primary 
anetoderma need not necessarily develop as a 
sequel of microthrombosis, because the finding of 
microthrombi is quite infrequently recorded in se-
rial sections of skin biopsy specimens. Also, the 
time of the occurrence of microthrombus cannot 
be definitely determined, i.e. whether it has oc-
curred in-between the onset of lesion and biopsy. 
The exact duration of lesions may occasionally be 
difficult to assess because some patients fail to 
observe skin alterations and it is the clinician who 
warns them of the lesions. Neither can the pos-
sible existence of skin alterations for months or 
even years be excluded, when the lesions are too 
old to demonstrate the presence of microthrombi. 
Yet, the existence of ischemic process has recent-
ly been emphasized (18). Alternatively, apart from 
microthrombosis and ischemia, antiphospholipid 
antibodies may also react with elastic fiber via an 
immune process. The existence has been postu-
lated of an epitope common to elastic fiber and 
membrane phospholipids to serve as a binding 
site for autoantibodies, with resultant immune re-
action upon binding (23).
 There is no efficient treatment for anetoderma. 
While attempts have been made with topical/intra-
lesional corticosteroid therapy, penicillin G, salicy-
lates, phenytoin, dapsone and vitamin E, none of 
these therapies has proved efficient (2).
CONCLUSION
 Based on the reports on patients in whom an-
etoderma preceded the occurrence of thrombotic 
event even by 20 years, we believe that all patients 
with anetoderma should undergo thorough testing 
for prothrombotic abnormalities, especially an-
tiphospholipid antibodies, using all tests available. 
There is no consensus on thrombosis prophylaxis 
in patients with a high titer of antiphospholipid 
antibodies but without thrombotic events in their 
history (27,31). Many authors do not support the 
prophylactic use of antiaggregation therapy (27). 
Even if we are inclined to believe that the prophy-
laxis of deep venous thrombosis and pulmonary 
embolism with regular doses of acetylsalicylic acid 
(aspirin 325) is inefficient (27,32), regular control 
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checkups are needed, along with warning the pa-
tient that such an event may occur.
 A finding of vasculitis with single vein endotheli-
al damage detected in histologic slide may be con-
sidered as evidence for the pathogenetic role of 
antiphospholipid antibodies in inducing dermal mi-
croinfarcts and ischemia, which would in turn lead 
to elastic fiber destruction. Like other authors (22), 
we believe that anetoderma should be included 
in the group of skin disorders in antiphospholipid 
syndrome.
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